Clinical trials: The Cardiac Function
Acute Coronary Syndrome
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate initial safety and efficacy of GW856553 in subjects with NSTEMI.
- Trial name
- Solstice (NCT00910962)
- Testing
- GW856553
- Where
- 108 sites in United States, Australia and 7 more
- Volunteers
- 526 people
- Sponsor
- GlaxoSmithKline
Coronary Heart Disease
A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients
This study will assess the safety, tolerability and efficacy of RO4607381 in patients with coronary heart disease (CHD) or CHD risk equivalents.
- Trial name
- NCT00655538
- Testing
- dalcetrapib
- Where
- 23 sites in Austria, France and 5 more
- Volunteers
- 476 people
- Sponsor
- Hoffmann-La Roche
Heart Failure
Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction
This was a randomized, double-blinded, placebo-controlled, multiple-dose study in subjects with stable heart failure (HF) with reduced ejection fraction (HFrEF).
- Trial name
- NCT02788747
- Testing
- 4 mg elamipretide, 40 mg elamipretide
- Where
- 15 sites in Italy, Netherlands and 1 more
- Volunteers
- 71 people
- Sponsor
- Stealth BioTherapeutics Inc.
Diabetes Mellitus Type 2
Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function
Vildagliptin and Sitagliptin both belong to the class of DPP-4 inhibitors, but differ in their pharmacokinetic profile as well as in their approved application (Vildagliptin, 2x 50 mg daily, Sitagliptin, 1x 100 mg daily).
- Trial name
- CGM-VISIT (NCT01686932)
- Testing
- Vildagliptin, Sitagliptin
- Where
- 11 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Hyperglycemia, Aortic Valve Replacement
The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose
The overall research plan is to test the hypothesis that intraoperative treatment of hyperinsulinemic normoglycemic clamp (HNC) in cardiac surgical patients improves myocardial function and short-term outcomes compared with…
- Conditions
- Hyperglycemia, Aortic Valve Replacement, Aortic Stenosis, Cardiac Surgery
- Trial name
- NCT01187329
- Testing
- hyperinsulinemic normoglycemic clamp (HNC), control group
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The Cleveland Clinic
Congenital Heart Disease
Acute Effects of Inhaled Treprostinil in Fontan Patients
In this pilot study investigators propose to explore the effects of a locally delivered inhaled pulmonary vasodilator (inhaled treprostinil) on exercise performance, pulmonary blood flow, venous pressure response and vascular…
- Trial name
- NCT02769624
- Testing
- Treprostinil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Heart Failure
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function
A study to assess the safety, tolerability, and pharmacokinetics of AMG 986 given orally as a single dose to healthy participants and participants with severely impaired kidney function.
- Trial name
- NCT03318809
- Testing
- AMG 986
- Where
- 4 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Amgen
Ankylosing Spondylitis
Effects of Etanercept on the Heart, Veins and Thickness of Certain Major Arteries In Ankylosing Spondylitis Patients
Study to assess whether etanercept therapy is able to increase flow-mediated vasodilatation in AS, and whether etanercept can modify the intima-media thickness (IMT) in these patients
- Trial name
- CREST (NCT00910273)
- Testing
- etanercept
- Where
- 4 sites in Italy
- Volunteers
- 34 people
- Sponsor
- Pfizer
Heart Failure, Cardiomyopathy
The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in Patients Undergoing LVAD Implantation
The main purpose of this research is to determine whether injecting mesenchymal precursor cells (MPC) into the heart during surgery to implant a left ventricular assist device (LVAD) is safe.
- Conditions
- Heart Failure, Cardiomyopathy, Ventricular Dysfunction
- Trial name
- NCT01442129
- Testing
- MPC Intramyocardial injection, Control Solution
- Where
- 11 sites in United States
- Volunteers
- 30 people
- Sponsor
- Deborah Ascheim
Cardiac Allograft Vasculopathy
Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
Many patients with end-stage heart failure, a condition in which the heart fails to pump enough blood to support the body's other organs, are fortunate enough to receive a heart transplant.
- Trial name
- NCT05373108
- Testing
- Macitentan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of California, Los Angeles
Atherosclerosis
Integrated Biomarker And Imaging Study - 2
IBIS-2 is a study using SB-480848 versus placebo in subjects with angiographically documented coronary heart disease. Endpoints include coronary imaging, endothelial function, biomarkers, safety and tolerability.
- Trial name
- NCT00268996
- Testing
- SB-480848
- Where
- 26 sites in Austria, Belgium and 9 more
- Volunteers
- 336 people
- Sponsor
- GlaxoSmithKline
Primary Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
This is an open-label, single-armed, prospective single-centre clinical study to evaluate the effect of riociguat on right heart size and function in patients with manifest PAH and CTEPH.
- Trial name
- RIVERII (NCT04954742)
- Testing
- Riociguat
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Heidelberg University
Mitral Regurgitation, Mitral Valve Regurgitation
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) and COAPT CAS
The purpose of the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) Trial is to confirm the safety and effectiveness of the MitraClip…
- Conditions
- Mitral Regurgitation, Mitral Valve Regurgitation, Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure Subjects, Heart Failure
- Trial name
- COAPT (NCT01626079)
- Testing
- MitraClip System
- Where
- 86 sites in United States, Canada
- Volunteers
- 776 people
- Sponsor
- Abbott Medical Devices
Physiological Changes in Deliberate Apnea
Evaluating the Influence of Apnea on Cardiac Function Using Cardiac Magnetic Resonance Imaging.
Former studies revealed a distinct pattern of changes in circulation during deliberate apnea. Blood pressure rises significantly often accompanied by bradycardia.
- Trial name
- NCT02280226
- Testing
- magnetic resonance imaging (MRI)
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Premature Ventricular Contractions, Congestive Heart Failure
Early Elimination of Premature Ventricular Contractions in Heart Failure
Premature ventricular contractions (PVC) are a very common irregular heart beat (arrhythmias) even in patients without heart disease. Frequent PVCs are thought to occur in about 1-4% of the general population.
- Trial name
- EVAC-HF (NCT01757067)
- Testing
- PVC ablation
- Where
- 8 sites in United States, Canada
- Volunteers
- 3 people
- Sponsor
- University of Maryland, Baltimore
Congestive Heart Failure
The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure
PP1- The purpose of this study is to determine whether giving more of the hormone produced by everyone called growth hormone releasing hormone (GHRH) can improve heart function in individuals with congestive heart failure.
- Trial name
- GHRH (NCT00791843)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Pennsylvania
Atrial Fibrillation, Heart Failure
The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure
The purpose of this study is to evaluate the efficacy of ranolazine in the prevention of recurrent atrial fibrillation in post-cardioversion patients with heart failure and preserved ejection fraction.
- Trial name
- RAD HF (NCT01887353)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Intermountain Health Care, Inc.
Heart Failure, Cardiomyopathies
The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy
Heart failure affects over 5.3 million Americans and, while other cardiovascular diseases have enjoyed a reduction in mortality rates over the last decade, the mortality from heart failure continues to rise[1].
- Trial name
- NCT00696410
- Testing
- Zinc Acetate
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Michigan
Congestive Heart Failure
A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure
The purpose of this study is to determine if Coreg CR is as effective as Coreg IR in improving heart function in subjects with stable chronic heart failure.
- Trial name
- COMPARE (NCT00323037)
- Testing
- carvedilol controlled release, carvedilol immediate release
- Where
- 75 sites in United States
- Volunteers
- 318 people
- Sponsor
- CTI-1, LLC
Type2 Diabetes, Heart Failure
Effect of Ertugliflozin on Cardiac Function in Diabetes
The aim of this study is to investigate the beneficial role of ertugliflozin, a new SGLT2 inhibitor, in cardiac function via measuring GLS as well as other hemodynamic factors using echocardiogram in patients with T2D and HF, who…
- Trial name
- ERTU-GLS (NCT03717194)
- Testing
- Ertugliflozin
- Where
- South Korea
- Volunteers
- 102 people
- Sponsor
- Soo Lim